HIV-Infected Children Can Transition to Efavirenz-Based Tx

This article originally appeared here.
Share this content:
HIV-Infected Children Can Transition to Efavirenz-Based Tx
HIV-Infected Children Can Transition to Efavirenz-Based Tx

TUESDAY, Nov. 3, 2015 (HealthDay News) -- For nevirapine-exposed children with HIV achieving initial viral suppression with ritonavir-boosted lopinavir-based therapy, transition to efavirenz-based therapy is not inferior to continuing ritonavir-boosted lopinavir-based therapy, according to a study published in the Nov. 3 issue of the Journal of the American Medical Association.

Ashraf Coovadia, M.B.Ch.B., from the University of Witwatersrand in Johannesburg, and colleagues conducted a randomized noninferiority trial involving 300 HIV-infected children exposed to nevirapine for prevention of mother-to-child transmission. Two hundred ninety-eight children with initial viral suppression were randomized to switch to efavirenz-based therapy (150 children) or to continue ritonavir-boosted lopinavir-based therapy (148 children); 98 percent were followed-up at 48 weeks after randomization.

The researchers found that the Kaplan-Meier probability of viral rebound by 48 weeks was 0.176 and 0.284 in the efavirenz and ritonavir-boosted lopinavir groups, respectively. The probabilities of viral failure were 0.027 and 0.020 in the efavirenz and ritonavir-boosted lopinavir groups, respectively. For viral rebound and viral failure, the risk differences were 0.107 and −0.007, respectively. For both end points, efavirenz was not inferior to ritonavir-boosted lopinavir (P < 0.001). CD4 cell percentage was 2.88 percent higher in the efavirenz group versus the ritonavir-boosted lopinavir group at 48 weeks.

"This study provides evidence to support the safety and efficacy of switching to efavirenz, the recommended drug for children older than 3 years, among children with viral suppression," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »